Gravity Analytica

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BLRX 11.20.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-25

Name of Upcoming Event:Conference Call

Full Press Release SEC Filings Our BLRX Tweets

About Gravity Analytica

Recent Filings

Management to Hold Conference Call at8:30 a.m. EST

TEL AVIV, Israel,Nov. 20, 2024/PRNewswire/ --BioLineRx Ltd.(NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter endedSeptember 30, 2024onMonday, November 25, 2024, before theU.S.markets open.

The Company will host a conference call at8:30 a.m. ESTfeaturing remarks byPhilip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from theU.S.or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through theevent pageon the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available untilNovember 27, 2024; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

AboutBioLineRx

BioLineRx Ltd.(NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide) with an indication in theU.S.for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered inIsrael, and with operations in theU.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it atwww.biolinerx.com, or onTwitterandLinkedIn.

CONTACTS:

United StatesJohn LaceyBioLineRxIR@biolinerx.com

IsraelMoran MeirLifeSci Advisors, LLCmoran@lifesciadvisors.com

Logo -https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2024-results-on-november-25-2024-302311395.html

SOURCEBioLineRx Ltd.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com